Open Access

Esculetin has therapeutic potential via the proapoptotic signaling pathway in A253 human submandibular salivary gland tumor cells

  • Authors:
    • Su-Bin Park
    • Woo Kwon Jung
    • Hyung Rae Kim
    • Hwa-Young Yu
    • Yong Hwan Kim
    • Junghyun Kim
  • View Affiliations

  • Published online on: June 22, 2022     https://doi.org/10.3892/etm.2022.11460
  • Article Number: 533
  • Copyright: © Park et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Esculetin is a natural lactone that is commonly derived from coumarins. According to previous experiments using human cancer cells, esculetin has potent antitumor activity; it also inhibits proliferation and induces the apoptosis of cancer cells. In the present study, the anti‑proliferative effect of esculetin on the submandibular salivary gland tumor cell line, A253, was evaluated via in vitro and in vivo analyses. Furthermore, the anti‑cancer effects of esculetin in A253 cells and a xenograft model of salivary gland tumors were determined using 3‑(4,5‑dimethylthiazol)‑2,5‑diphenyltetrazolium bromide and TUNEL assay, apoptosis protein array, quantitative polymerase chain reaction and western blot analysis. Esculetin (50‑150 µM) was demonstrated to have an anti‑proliferative effect in the A253 cell line in vitro; this observed effect was dependent on the dose and duration of treatment. Esculetin also increased the levels of Bax, cleaved caspase‑3, cleaved‑9 and cleaved poly (ADP‑ribose) polymerase apoptosis‑related proteins, and decreased the expression levels of the Bcl‑2 anti‑apoptotic protein. With respect to apoptosis regulation, esculetin significantly decreased the proliferation of tumor cells in a xenograft model (100 mg/kg/day) for 18 days. Overall, esculetin could be a potential oral anticancer drug against salivary gland cancer.

Related Articles

Journal Cover

August-2022
Volume 24 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Park S, Jung WK, Kim HR, Yu H, Kim YH and Kim J: Esculetin has therapeutic potential via the proapoptotic signaling pathway in A253 human submandibular salivary gland tumor cells. Exp Ther Med 24: 533, 2022
APA
Park, S., Jung, W.K., Kim, H.R., Yu, H., Kim, Y.H., & Kim, J. (2022). Esculetin has therapeutic potential via the proapoptotic signaling pathway in A253 human submandibular salivary gland tumor cells. Experimental and Therapeutic Medicine, 24, 533. https://doi.org/10.3892/etm.2022.11460
MLA
Park, S., Jung, W. K., Kim, H. R., Yu, H., Kim, Y. H., Kim, J."Esculetin has therapeutic potential via the proapoptotic signaling pathway in A253 human submandibular salivary gland tumor cells". Experimental and Therapeutic Medicine 24.2 (2022): 533.
Chicago
Park, S., Jung, W. K., Kim, H. R., Yu, H., Kim, Y. H., Kim, J."Esculetin has therapeutic potential via the proapoptotic signaling pathway in A253 human submandibular salivary gland tumor cells". Experimental and Therapeutic Medicine 24, no. 2 (2022): 533. https://doi.org/10.3892/etm.2022.11460